TY - JOUR T1 - Impact of CMV and EBV on Immune Recovery After Allogeneic Hematopoietic Cell Transplantation in Children JF - Anticancer Research JO - Anticancer Res SP - 6009 LP - 6013 DO - 10.21873/anticanres.12950 VL - 38 IS - 10 AU - EWELINA PUKOWNIK AU - MALGORZATA KUBICKA AU - BEATA KURYLO-RAFINSKA AU - ROBERT DEBSKI AU - PRZEMYSLAW GALAZKA AU - KRZYSZTOF CZYZEWSKI AU - ANNA KRENSKA AU - NATALIA BARTOSZEWICZ AU - EWA DEMIDOWICZ AU - AGATA MARJAĊƒSKA AU - MAGDALENA DZIEDZIC AU - MONIKA POGORZALA AU - MARIUSZ WYSOCKI AU - JAN STYCZYNSKI Y1 - 2018/10/01 UR - http://ar.iiarjournals.org/content/38/10/6009.abstract N2 - Background/Aim: Immune recovery is a key factor in the management of patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study analyzed the factors contributing to immune reconstitution after allo-HSCT. Patients and Methods: Overall, 65 children with malignant or non-malignant diseases were included in multivariate analyses. Results: The following factors contributed to a faster immune recovery: peripheral blood as a stem cell source and reactivation of CMV infection for CD3+ and CD4+ lymphocyte subpopulations; reactivation of CMV infection for CD8+ subset; donor EBV-IgG+ and no EBV reactivation for CD19 lymphocytes; recipient age below 10 years and peripheral blood as a stem cell source for NK cells. For CD2 and CD4/CD8 ratio no factor was significant in multivariate analysis. Conclusion: Patients receiving a graft from an EBV-IgG-positive donor and not having early EBV post-transplant viremia show faster recovery of the B-cells, while patients with early CMV-DNA-emia have a better re-establishment of T-cell subsets. ER -